Conference abstractPublished 11 Aug 2015
Expanding the scope of fragment screening libraries: Thinking in 3D
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fragment-based drug discovery (FBDD) methods are a proven strategy for hit identification, providing diverse, high quality start points for numerous drug discovery programmes. Many fragment hits have been optimised and transitioned to the clinical setting with one, namely Vemurafenib gaining FDA approval to treat late stage V600E mutant B-Raf driven malignant melanoma. Critical for successful fragment screening is a high quality compound library. Whilst fragment screening techniques have evolved over the years, increasing in sensitivity and throughput, fragment library molecules have received less attention. Many fragment libraries are chemically diverse and have been selected based on a good balance of properties, however, they all tend to have limited 3-dimensional diversity, typically being composed of flat sp2-rich aromatic and heteroaromatic compounds. This move towards “flatter” molecules not only reduces the sampling of chemical space available for fragments but also fails to capitalise on the additional attributes of sp3 character. Recently, two groups have independently published data showing the improvements in profile and project progression by, for example, increasing the proportion of sp3 centres contained in molecules or reducing lipohilicity. In addition, there are multiple examples in the literature reporting the positive impact of increasing sp3ness or 3-dimensionality through inducing conformational twist. This talk will discuss fragment library composition along with suggestions and practical examples of how future, more structurally diverse fragments which occupy different regions of chemical space to the vast majority of current fragment libraries can be designed and selected.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Angelo Pugliese”
